DE69426527D1 - Verfahren zur herstellung von fusionsproteinen, die scfv fragmente enthalten, in transformierten schimmelpilzen - Google Patents

Verfahren zur herstellung von fusionsproteinen, die scfv fragmente enthalten, in transformierten schimmelpilzen

Info

Publication number
DE69426527D1
DE69426527D1 DE69426527T DE69426527T DE69426527D1 DE 69426527 D1 DE69426527 D1 DE 69426527D1 DE 69426527 T DE69426527 T DE 69426527T DE 69426527 T DE69426527 T DE 69426527T DE 69426527 D1 DE69426527 D1 DE 69426527D1
Authority
DE
Germany
Prior art keywords
gene
aspergillus
present
scfv
mould
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69426527T
Other languages
English (en)
Other versions
DE69426527T2 (de
Inventor
Leon Gerardus Joseph Frenken
Gorcom Robert F M Van
Johanna G M Hessing
Den Hondel Cornelis Antoni Van
Wouter Musters
Johannes Mariaa Verbakel
Cornelis Theodorus Verrips
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Unilever PLC
Nederlandse Organisatie voor Toegepast Natuurwetenschappelijk Onderzoek TNO
Unilever NV
Original Assignee
Unilever PLC
Nederlandse Organisatie voor Toegepast Natuurwetenschappelijk Onderzoek TNO
Unilever NV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Unilever PLC, Nederlandse Organisatie voor Toegepast Natuurwetenschappelijk Onderzoek TNO, Unilever NV filed Critical Unilever PLC
Publication of DE69426527D1 publication Critical patent/DE69426527D1/de
Application granted granted Critical
Publication of DE69426527T2 publication Critical patent/DE69426527T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/26—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against hormones ; against hormone releasing or inhibiting factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/80—Vectors or expression systems specially adapted for eukaryotic hosts for fungi
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/036—Fusion polypeptide containing a localisation/targetting motif targeting to the medium outside of the cell, e.g. type III secretion
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/50—Fusion polypeptide containing protease site
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
    • C07K2319/75—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor containing a fusion for activation of a cell surface receptor, e.g. thrombopoeitin, NPY and other peptide hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Endocrinology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Cosmetics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DE69426527T 1993-06-09 1994-06-09 Verfahren zur herstellung von fusionsproteinen, die scfv fragmente enthalten, in transformierten schimmelpilzen Expired - Fee Related DE69426527T2 (de)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP93201661 1993-06-09
EP93201660 1993-06-09
EP93201706 1993-06-14
PCT/EP1994/001906 WO1994029457A2 (en) 1993-06-09 1994-06-09 Process for producing fusion proteins comprising scfv fragments by a transformed mould

Publications (2)

Publication Number Publication Date
DE69426527D1 true DE69426527D1 (de) 2001-02-08
DE69426527T2 DE69426527T2 (de) 2001-08-30

Family

ID=27235312

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69426527T Expired - Fee Related DE69426527T2 (de) 1993-06-09 1994-06-09 Verfahren zur herstellung von fusionsproteinen, die scfv fragmente enthalten, in transformierten schimmelpilzen

Country Status (10)

Country Link
EP (1) EP0702721B1 (de)
JP (1) JPH08511160A (de)
AT (1) ATE198490T1 (de)
AU (1) AU7123494A (de)
CA (1) CA2162878A1 (de)
DE (1) DE69426527T2 (de)
DK (1) DK0702721T3 (de)
ES (1) ES2155854T3 (de)
FI (1) FI114870B (de)
WO (1) WO1994029457A2 (de)

Families Citing this family (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9504344D0 (en) * 1995-03-03 1995-04-19 Unilever Plc Antibody fragment production
EP0826054B1 (de) * 1995-05-18 2003-12-17 Genencor International, Inc. Glykosyltransferase expression in aspergillus
TR199903037T2 (xx) 1997-06-13 2000-06-21 Unilever N.V. A�art�c� enzimler.
ATE535154T1 (de) 1998-03-12 2011-12-15 Vhsquared Ltd Produkten die inaktivierte hefen oder schimmel enthalten, die auf ihrer aussenoberfläche aktive antikörper haben
EP0954978B1 (de) 1998-03-12 2011-11-30 VHsquared Limited Produkten die inaktivierte Hefen oder Schimmel enthalten, die auf ihrer Aussenoberfläche aktive Antikörper haben
BR0012711A (pt) 1999-07-27 2002-04-09 Unilever Nv Composição detergente enzimática, e, processos para aumentar a atividade e / ou a estabilidade de uma oxidorredutase dependente de co-fator e para branquear manchas presentes em tecidos
DE60139811D1 (de) 2000-12-19 2009-10-15 Unilever Nv Stabilisierung von schwerkettigen Kamelantikörpern durch Kaliumsalze
NZ534687A (en) * 2002-01-28 2007-10-26 Medarex Inc Human monoclonal antibodies to prostate specific membrane antigen (PSMA) seq id 54
HUE045710T2 (hu) 2005-05-18 2020-01-28 Ablynx Nv Javított, alfa tumor nekrózis faktor elleni nanobodies
BRPI0609797B8 (pt) 2005-05-20 2021-05-25 Ablynx Nv nanocorpos melhorados para o tratamento de desordens mediadas por agregação
EP2115004A2 (de) 2006-12-19 2009-11-11 Ablynx N.V. Gegen gpcrs gerichtete aminosäuresequenzen und diese enthaltende polypeptide zur behandlung von mit gpcr in zusammenhang tehenden krankheiten und erkrankungen
WO2008074840A2 (en) 2006-12-19 2008-06-26 Ablynx N.V. Amino acid sequences directed against a metalloproteinase from the adam family and polypeptides comprising the same for the treatment of adam-related diseases and disorders
US20100062491A1 (en) * 2007-01-05 2010-03-11 Novozymes A/S Overexpression of the Chaperone BIP in a Heterokaryon
EP2260058A2 (de) 2008-04-07 2010-12-15 Ablynx N.V. Variable einzeldomänen gegen notch-signalwege
EP2417163B1 (de) 2009-04-10 2019-02-27 Ablynx N.V. Verbesserte, gegen il-6r gerichtete aminosauresequenzen und polypeptide, die diese enthalten, zur behandlung von erkrankungen und storungen, die mit il-6r in zusammenhang stehen
DK2427486T3 (en) 2009-05-07 2015-05-26 Novozymes Biopharma Dk As A process for purifying albumin
CN102459332B (zh) 2009-06-05 2015-08-19 埃博灵克斯股份有限公司 用于预防和/或治疗呼吸道感染的单价、二价和三价抗人呼吸道合胞病毒(hrsv)纳米抗体构建体
EP2507262A1 (de) 2009-11-30 2012-10-10 Ablynx N.V. Verbesserte gegen hrsv gerichtete aminosäuresequenzen und polypeptide damit zur prävention und/oder behandlung von atemwegsinfektionen
WO2011073180A1 (en) 2009-12-14 2011-06-23 Ablynx N.V. Single variable domain antibodies against ox40l, constructs and therapeutic use
WO2011083140A1 (en) 2010-01-08 2011-07-14 Ablynx Nv Immunoglobulin single variable domain directed against human cxcr4
US9120855B2 (en) 2010-02-10 2015-09-01 Novartis Ag Biologic compounds directed against death receptor 5
EP2552962B1 (de) 2010-03-26 2016-03-23 Ablynx N.V. Einzelne, gegen cxcr7 gerichtete variable immunoglobulindomänen
AU2011254557B2 (en) 2010-05-20 2015-09-03 Ablynx Nv Biological materials related to HER3
WO2012042026A1 (en) 2010-09-30 2012-04-05 Ablynx Nv Biological materials related to c-met
AU2011328246B2 (en) 2010-11-08 2016-06-30 Ablynx N.V. CXCR2 binding polypeptides
US20150158948A9 (en) 2011-03-28 2015-06-11 Francis Descamps Bispecific anti-cxcr7 immunoglobulin single variable domains
UA117218C2 (uk) 2011-05-05 2018-07-10 Мерк Патент Гмбх Поліпептид, спрямований проти il-17a, il-17f та/або il17-a/f
EP2723772A1 (de) 2011-06-23 2014-04-30 Ablynx N.V. Gegen ige gerichtete variable immunglobulin-einzeldomänen
CA2850261C (en) 2011-09-30 2021-04-20 Ablynx Nv C-met immunoglobulin single variable domains
US9328174B2 (en) 2012-05-09 2016-05-03 Novartis Ag Chemokine receptor binding polypeptides
WO2014087010A1 (en) 2012-12-07 2014-06-12 Ablynx N.V. IMPROVED POLYPEPTIDES DIRECTED AGAINST IgE
AU2014272024B2 (en) 2013-05-29 2018-03-15 Vybion, Inc. Single chain intrabodies that alter huntingtin mutant degradation
NL2013661B1 (en) 2014-10-21 2016-10-05 Ablynx Nv KV1.3 Binding immunoglobulins.
CN107406497A (zh) 2014-12-19 2017-11-28 埃博灵克斯股份有限公司 半胱氨酸连接的纳米抗体二聚体
EP4345112A2 (de) 2015-05-13 2024-04-03 Ablynx N.V. T-zell-rekrutierende polypeptide auf basis der cd3-reaktivität
US10927186B2 (en) 2015-05-13 2021-02-23 Ablynx N.V. T cell recruiting polypeptides based on TCR alpha/beta reactivity
WO2017013270A1 (en) 2015-07-23 2017-01-26 Universite De Strasbourg Use of leptin signaling inhibitor for protecting kidneys from patients having ciliopathy
MX2018010485A (es) 2016-03-04 2019-01-10 Jn Biosciences Llc Anticuerpos para inmunoreceptor de celulas t con dominios de ig e itim (tigit).
EP3526253A1 (de) 2016-10-14 2019-08-21 Institut Curie Neuer anti-lsp1-antikörper
KR102665596B1 (ko) 2016-11-16 2024-05-14 아블린쓰 엔.브이. Cd123 및 tcr 알파/베타에 결합할 수 있는 t 세포 동원 폴리펩티드
EP3624854A1 (de) 2017-05-16 2020-03-25 Université de Strasbourg Proteinwirkstoffkonjugate und deren verwendung in der behandlung von krebs
TWI826376B (zh) 2017-06-02 2023-12-21 德商麥克專利有限公司 與ａｄａｍｔｓ５、ｍｍｐ１３及聚集蛋白聚醣結合的多肽
MX2019014400A (es) 2017-06-02 2020-02-10 Merck Patent Gmbh Inmunoglobulinas que se unen a adamts.
BR112019025097A2 (pt) 2017-06-02 2020-07-28 Merck Patent Gmbh imunoglobulinas de ligação a mmp13
WO2018220225A1 (en) 2017-06-02 2018-12-06 Ablynx Nv Aggrecan binding immunoglobulins
US20200371105A1 (en) 2017-07-28 2020-11-26 Institut Curie New subpopulations of cancer associated fibroblasts as prognosis markers for immunotherapy treatments
JP7266611B2 (ja) 2018-02-26 2023-04-28 アブリンクス・エヌ・フェー ペプチドリンカーをコードする改良されたヌクレオチド配列
KR101875564B1 (ko) * 2018-05-24 2018-07-09 국민대학교산학협력단 포도당 및 글리세롤을 이용한 유가식 배양을 통한 리시놀레산으로 오메가-하이드록시운덱-9-에논산의 생물전환공정
EP3636657A1 (de) 2018-10-08 2020-04-15 Ablynx N.V. Chromatographiefreies antikörperreinigungsverfahren
WO2020245663A1 (en) 2019-06-01 2020-12-10 Institut Pasteur Nanobody-based ns1 assay for the specific diagnosis of acute zika virus infection
MX2022015157A (es) 2020-06-02 2023-01-16 Arcus Biosciences Inc Anticuerpos para tigit.
MX2023007299A (es) 2020-12-18 2023-07-04 Ablynx Nv Polipeptidos de reclutamiento de celulas t basados en la reactividad de tcr alfa/beta.
EP4337691A1 (de) 2021-05-12 2024-03-20 Université de Strasbourg Für phosphoryliertes h2ax spezifischer einzeldomänenantikörper und dessen verwendungen
WO2023151894A1 (en) 2022-02-11 2023-08-17 Henkel Ag & Co. Kgaa Process for the synthesis of alpha-methylene-gamma-butyrolactone
US20240132624A1 (en) 2022-07-27 2024-04-25 Ablynx N.V. Polypeptides binding to a specific epitope of the neonatal fc receptor
WO2024083843A1 (en) 2022-10-18 2024-04-25 Confo Therapeutics N.V. Amino acid sequences directed against the melanocortin 4 receptor and polypeptides comprising the same for the treatment of mc4r-related diseases and disorders

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0539395A1 (de) * 1990-07-16 1993-05-05 Alko Group Ltd. Immunglobulinherstellung durch trichoderma
WO1993008300A1 (en) * 1991-10-18 1993-04-29 The University Of Calgary Expression-secretion vectors for the production of biologically active fv fragments
IT1270866B (it) * 1993-03-10 1997-05-13 Eniricerche Spa Vettore ricombinante e suo impiego per la preparazione esocellulare di anticorpi in forma di singola molecola da bacillus subtilis

Also Published As

Publication number Publication date
ATE198490T1 (de) 2001-01-15
DK0702721T3 (da) 2001-05-21
WO1994029457A3 (en) 1995-03-09
EP0702721B1 (de) 2001-01-03
CA2162878A1 (en) 1994-12-22
FI114870B (fi) 2005-01-14
ES2155854T3 (es) 2001-06-01
WO1994029457A2 (en) 1994-12-22
AU7123494A (en) 1995-01-03
FI955446A0 (fi) 1995-11-13
JPH08511160A (ja) 1996-11-26
FI955446A (fi) 1995-12-11
EP0702721A1 (de) 1996-03-27
DE69426527T2 (de) 2001-08-30

Similar Documents

Publication Publication Date Title
DE69426527T2 (de) Verfahren zur herstellung von fusionsproteinen, die scfv fragmente enthalten, in transformierten schimmelpilzen
DE3885983T2 (de) Verfahren zur Herstellung des rekombinanten menschlichen Faktors VIII:C.
ATE121781T1 (de) Verwendung von dns-fragmenten, die ein signalpeptid kodieren zur sekretion von reifen proteinen in rekombinanten hefen, expressions- kassetten, transformierte hefen und verfahren zur herstellung dieser proteine.
EP0042246A2 (de) Plasmid
FI973468A (fi) Hampaiden valkaisemiseen tai ihon ja limakalvojen sairauksien hoitoon käytettävien valmisteiden valmistusmenetelmä
EP0132732A3 (en) Homologues from aprotinine whose lys 15 amino acid is substituted by other amino acids, process for their preparation and their use as medicaments
HUT46356A (en) Process for producing the preprotein of apc polypeptide and the dna encoding it, as well as for the diagnostic utilization of the dna and the protein
GB9220667D0 (en) Improvements in or relating to dioic acids
ZA929539B (en) Process for producing/secreting a protein by a transformed mould using expression/secretion regulating regions derived from an aspergillus endoxylanase II G
DE3471092D1 (en) Composition essentially consisting of trans-1-(2,6,6-trimethylcyclohexyl)-hexan-3-ol, utilization of same and process for its preparation; cycloaliphatic ketone and alcohol intermediates
ATE233314T1 (de) Eine sekretionssequenz für die herstellung von heterologen proteinen in hefe
PL321039A1 (en) Production of human insulin
CA2286366A1 (en) Transgenic expression in genital tract and sexual accessory glands
DE3583220D1 (de) Verwendung von dipeptidderivaten fuer die herstellung von arzneimitteln zur behandlung von an amyotropher lateralsklerose erkrankten.
Slavkin et al. Molecular aspects of tooth morphogenesis and differentiation
BR9609041A (pt) "terapia de substituição para cáries dentais".
DE3175357D1 (en) Dna sequences encoding various allelic forms of mature thaumatin, recombinant plasmids comprising said dna's and a process for their preparation, bacterial cultures comprising said recombinant plasmids, and method for producing mature thaumatin
HU9401604D0 (en) Production of proteins using fb2 protein
HUP9904219A2 (hu) Eljárás és készítmények interferon-alfa-nukleinsavak bevitelére és expressziójára
EP0587571A4 (de) Humanes galanin, cdna-klone die für humanes galanin kodieren und eine methode humanes galamin herzustellen.
PT93614A (pt) Estirpe de levedura melhorada para a producao de proteinas heterologas maduras,em particular hirudina, e processo para a preparacao da hirudina correspondente
DE69530647D1 (de) Für biosynthetische Insulinvorstufen kodierende DNA-Sequenzen und Verfahren zur Herstellung von Insulin
DE3767629D1 (de) Menschlicher b-zellen-differenzierungsfaktor und verfahren zu dessen herstellung.
ATE224403T1 (de) Verwendung von kaseinfragmenten als wachstumerförderer
GR3034006T3 (en) Method for obtaining an increased production of a producing celline by using a fusion protocol.

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee